Cargando…
Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241540/ https://www.ncbi.nlm.nih.gov/pubmed/35477313 http://dx.doi.org/10.1128/msphere.00104-22 |
_version_ | 1784737829163630592 |
---|---|
author | Breen, Paul Zimbric, Madsen Opron, Kristopher Caverly, Lindsay J. |
author_facet | Breen, Paul Zimbric, Madsen Opron, Kristopher Caverly, Lindsay J. |
author_sort | Breen, Paul |
collection | PubMed |
description | Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a host risk factor for NTM infection. In this study, 69 sputum samples were collected from 59 people with CF; 42 samples from 32 subjects with NTM infection (14 samples collected before incident NTM infection and 28 samples collected following incident NTM infection) were compared to 27 samples from 27 subjects without NTM infection. Sputum samples were analyzed with 16S rRNA gene sequencing and metabolomics. A supervised classification and correlation analysis framework (sparse partial least-squares discriminant analysis [sPLS-DA]) was used to identify correlations between the microbial and metabolomic profiles of the NTM cases compared to the NTM-negative controls. Several metabolites significantly differed in the NTM cases compared to controls, including decreased levels of tryptophan-associated and branched-chain amino acid metabolites, while compounds involved in phospholipid metabolism displayed increased levels. When the metabolome and microbiome data were integrated by sPLS-DA, the models and component ordinations showed separation between the NTM and control samples. While this study could not determine if the observed differences in sputum metabolites between the cohorts reflect metabolic changes that occurred as a result of the NTM infection or metabolic features that contributed to NTM acquisition, it is hypothesis generating for future work to investigate host and bacterial community factors that may contribute to NTM infection risk in CF. IMPORTANCE Host risk factors for nontuberculous mycobacterial (NTM) infection in people with cystic fibrosis (CF) are largely unclear. The goal of this study was to help identify potential host and bacterial community risk factors for NTM infection in people with CF, using microbiome and metabolome data from CF sputum samples. The data obtained in this study identified several metabolic profile differences in sputum associated with NTM infection in CF, including 2-methylcitrate/homocitrate and selected ceramides. These findings represent potential risk factors and therapeutic targets for preventing and/or treating NTM infections in people with CF. |
format | Online Article Text |
id | pubmed-9241540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92415402022-06-30 Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis Breen, Paul Zimbric, Madsen Opron, Kristopher Caverly, Lindsay J. mSphere Research Article Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a host risk factor for NTM infection. In this study, 69 sputum samples were collected from 59 people with CF; 42 samples from 32 subjects with NTM infection (14 samples collected before incident NTM infection and 28 samples collected following incident NTM infection) were compared to 27 samples from 27 subjects without NTM infection. Sputum samples were analyzed with 16S rRNA gene sequencing and metabolomics. A supervised classification and correlation analysis framework (sparse partial least-squares discriminant analysis [sPLS-DA]) was used to identify correlations between the microbial and metabolomic profiles of the NTM cases compared to the NTM-negative controls. Several metabolites significantly differed in the NTM cases compared to controls, including decreased levels of tryptophan-associated and branched-chain amino acid metabolites, while compounds involved in phospholipid metabolism displayed increased levels. When the metabolome and microbiome data were integrated by sPLS-DA, the models and component ordinations showed separation between the NTM and control samples. While this study could not determine if the observed differences in sputum metabolites between the cohorts reflect metabolic changes that occurred as a result of the NTM infection or metabolic features that contributed to NTM acquisition, it is hypothesis generating for future work to investigate host and bacterial community factors that may contribute to NTM infection risk in CF. IMPORTANCE Host risk factors for nontuberculous mycobacterial (NTM) infection in people with cystic fibrosis (CF) are largely unclear. The goal of this study was to help identify potential host and bacterial community risk factors for NTM infection in people with CF, using microbiome and metabolome data from CF sputum samples. The data obtained in this study identified several metabolic profile differences in sputum associated with NTM infection in CF, including 2-methylcitrate/homocitrate and selected ceramides. These findings represent potential risk factors and therapeutic targets for preventing and/or treating NTM infections in people with CF. American Society for Microbiology 2022-04-28 /pmc/articles/PMC9241540/ /pubmed/35477313 http://dx.doi.org/10.1128/msphere.00104-22 Text en Copyright © 2022 Breen et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Breen, Paul Zimbric, Madsen Opron, Kristopher Caverly, Lindsay J. Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title | Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title_full | Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title_fullStr | Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title_full_unstemmed | Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title_short | Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis |
title_sort | sputum metabolites associated with nontuberculous mycobacterial infection in cystic fibrosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241540/ https://www.ncbi.nlm.nih.gov/pubmed/35477313 http://dx.doi.org/10.1128/msphere.00104-22 |
work_keys_str_mv | AT breenpaul sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis AT zimbricmadsen sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis AT opronkristopher sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis AT caverlylindsayj sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis |